Download PDF – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call
Category: Press Release
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
Download PDF BOSTON, July 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
Download PDF – This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada – – AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 – BOSTON, June 22, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq:
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
Download PDF BOSTON, June 21, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
Download PDF Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrated promising activity in nccRCC patients, a difficult to treat patient population
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
Download PDF BOSTON, May 18, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time. A live webcast of the fireside chat can be accessed by
AVEO Oncology Reports First Quarter 2022 Financial Results
Download PDF – Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, May 05, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
Download PDF BOSTON, April 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and provide
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
Download PDF – Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021 – – Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Long-term data from pivotal TIVO-3 study presented at ASCO GU
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
Download PDF BOSTON, March 07, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2022, to discuss the financial results and provide